Celgene issued a letter to healthcare professionals in November warning of suicidal ideation/behaviour that have been reported from clinical trials and postmarketing experience (with/without history of depression) at uncommon frequency (≥1/1,000 to ≤1/100) in patients on apremilast. Cases of completed suicide were also reported postmarketing.